Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $100.9 million.

  • United Therapeutics' Other Operating Expenses rose 2142.0% to $100.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $356.9 million, marking a year-over-year increase of 1709.32%. This contributed to the annual value of $309.7 million for FY2024, which is 2027.18% up from last year.
  • As of Q3 2025, United Therapeutics' Other Operating Expenses stood at $100.9 million, which was up 2142.0% from $87.6 million recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Other Operating Expenses ranged from a high of $140.2 million in Q1 2021 and a low of $25.9 million during Q1 2022
  • Moreover, its 5-year median value for Other Operating Expenses was $70.1 million (2023), whereas its average is $65.2 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first crashed by 8211.89% in 2021, then soared by 11582.49% in 2023.
  • United Therapeutics' Other Operating Expenses (Quarter) stood at $34.6 million in 2021, then soared by 69.94% to $58.8 million in 2022, then grew by 20.75% to $71.0 million in 2023, then increased by 6.9% to $75.9 million in 2024, then surged by 32.94% to $100.9 million in 2025.
  • Its Other Operating Expenses was $100.9 million in Q3 2025, compared to $87.6 million in Q2 2025 and $92.5 million in Q1 2025.